Copy Link Print Information

Everolimus

(Synonyms: RAD001; SDZ-RAD)
119 Cited Publications
Kundenbewertung

Based on 119 publication(s) in Google Scholar

Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective, orally active, blood-brain barrier-permeable mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • Reinheit: 99.85%
  • CAS. Nr.: 159351-69-6
  • Formel: C53H83NO14
  • Molecular Weight:958.22
  • Speicherung:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 1 year , -20°C, 6 months
  • Everolimus Chemical Structure
    Everolimus Chemical Structure
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
  • Experimental Validation Results for Everolimus
CAS. Nr.: 159351-69-6
Größe
Preis
Verfügbarkeit
Menge
Amount: USD 0.00
Please select quantity
or
or

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Everolimus:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Finden Sie Ihren Händler vor Ort Your local distributor: Hycultec GmbHHycultec
  • Biologische Aktivität
  • Chemical Information
  • Lösungsmittel & Löslichkeit
  • Protokoll
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Everolimus

More
Customer Validation & Images
WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB

Alle mTOR Isoform-spezifische Produkte anzeigen

More
Keywords
MOQ
Minimum order quantity
100 mg

Angebot einholen Auf Lager

Other size
Angebot einholen
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Einloggen
Registrieren
Sign in to MedChemExpress
Neuen Account Registrieren

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Everolimus Chemical Structure
    Everolimus Chemical Structure
    1/16
  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2020 Jun;10(6):1004-1019. [Abstract]

    Customer Validation
     ECa109 cells stably transfected with control shRNA or RICTOR shRNA were treated with RAD001 (10 μmol/L) or PP242 (2 μmol/L) for 48 h, and total proteins were extracted to analysis the expression of RICTOR, p-AKT (Ser473), AKT, p-PRAS40 (Thr246), PRAS40, p-p70S6K and p70S6K by Western blot (n=5).

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2020 Jun;10(6):1004-1019. [Abstract]

    Customer Validation
     Total proteins in tumor tissues from nude mice were extracted and the expressions of RICTOR, p-AKT (Ser473), AKT, p-PRAS40 (Thr246), PRAS40, p-p70S6K (Thr389) and p70S6K were evaluated by Western blot (n=5). Values represent the mean±SD.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Mol Cancer Res. 2019 Jan;17(1):42-53. [Abstract]

    Customer Validation
     Combination of Everolimus with AZD2281 (left panel) and AZD2014 with AZD2281 (right panel) activates the RIPK1 Ser 166 phosphorylation in Clone A and SF-539 cells respectively.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Prostate. 2019 Jan;79(1):44-53. [Abstract]

    Customer Validation
     Treatment with sub-dose of Everolimus (10 nM), together with CQ (5 µM) increases the levels of Bax and cleaved PARP, and decreases the levels of Bcl-2 expression in both PC3 and LNPER cells.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2018 Apr 19:12:911-920. [Abstract]

    Customer Validation
     786-O and A498 cell lines are treated by RAD001 with different concentrations for 24 hours. Immunoblotting shows that RAD001 induces autophagy indicators including upregulation of LC3-II/I and downregulation of p62 in a dose-dependent manner.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2018 Apr 19:12:911-920. [Abstract]

    Customer Validation
     Immunoblotting demonstrates that AZD6244 can effectively restore upregulation of LC3-II/I and downregulation of p62 induced by RAD001 in 786-O and A498 cells.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Nutrients. 2018 Dec 8;10(12). pii: E1950. [Abstract]

    Customer Validation
     Western analysis of protein expression in cells treatmented with or without PLX4032 or RAD001.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111. [Abstract]

    Customer Validation
     ED-40415 cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, everolimus, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111. [Abstract]

    Customer Validation
     HUT-102 cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, everolimus, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111. [Abstract]

    Customer Validation
     MT-2 cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, everolimus, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111. [Abstract]

    Customer Validation
     ATL-43T cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, everolimus, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2017 Nov 1:408:43-54. [Abstract]

    Customer Validation
     Western blot analysis of p-p70S6k, p70S6k, p-AKT and AKT after 6 h of treatment with 20 μM Everolimus. Levels of p-p70S6k and p-AKT are quantified by densitometric analysis and a corresponding histogram is constructed as relative to p70S6k or AKT and α-tubulin. The lower panel shows a representative Western blot.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Molecules. 2017 Dec 12;22(12). pii: E2207. [Abstract]

    Customer Validation
     p-AKT level in NRK cells treated with 5 nM RAD-001, 1 μM Resveratrol and their combination for 2 h and analyzed by Western blotting. Blots from 3 independent experiments are used for quantification.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: PLoS One. 2016 Jan 28;11(1):e0147682. [Abstract]

    Customer Validation
     CHP-212 and SK-N-AS cells are treated with indicated concentrations of AZD6244, MEK162, Everolimus or AZD8055 or combinations thereof as indicated for 1 hour. Then, cells are lysed and analysed by Western blot. Phosphorylation levels of AKT, ERK and S6 are detected by specific anti-phospho antibodies. Loading is verified by specific antibodies to total AKT, ERK and anti-tubulin.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Oncotarget. 2015 Dec 8;6(39):42183-96. [Abstract]

    Customer Validation
     KNS-62 and T24 cells are treated with 250 nM AZD6244, 250 nM MEK162, 5 nM of Everolimus, 250 nM AKT8055 or combinations thereof as indicated for 1 hour. Then, cells are lysed and analysed by Western blot.

  • 1/16

    Everolimus purchased from MedChemExpress. Usage Cited in: Sci Transl Med. 2013 Jul 31;5(196):196ra99. [Abstract]

    Customer Validation
     Apoptosis and PI3K/Akt/mTOR pathway inhibition in cells treated with BYL719, RAD001, or the combination. Protein lysates from HCC1954 and JIMT-1 cells treated for 18 hours with 0.5 μM BYL719, 1 nM RAD001 or the combination are analyzed by immunoblotting against the indicated proteins. Data are shown as mean ± SEM. p-value is calculated using two-sided student’s t-test.

  • Everolimus